Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 7/20 | 0.46 |
| ▸ | STAT6 | P42226 | 4/20 | 0.44 |
| ▸ | TTK | P33981 | 2/20 | 0.43 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19921166 | 0.92 | STAT6 (0.53) | PTK2STAT6JAK2JAK3IRAK4 | |
| SCHEMBL19921188 | 0.91 | PTK2 (0.52) | PTK2STAT6JAK2JAK3BRD4 | |
| SCHEMBL19921159 | 0.88 | PTK2 (0.58) | PTK2TTKFESFLT3JAK2 | |
| SCHEMBL21150147 | 0.85 | IRAK4 (0.54) | PTK2STAT6TTKFESFLT3 | |
| SCHEMBL19921070 | 0.85 | STAT6 (0.43) | STAT6JAK2JAK3IRAK4 | |
| SCHEMBL20547121 | 0.83 | STAT6 (0.51) | STAT6JAK2JAK3IRAK4 | |
| SCHEMBL19921147 | 0.82 | PDE5A (0.47) | PTK2 | |
| SCHEMBL19921146 | 0.82 | PTK2 (0.62) | PTK2STAT6JAK2JAK3ALK | |
| SCHEMBL19921189 | 0.81 | TTK (0.39) | PTK2STAT6TTKFESFLT3 | |
| SCHEMBL19921167 | 0.81 | PTK2 (0.51) | PTK2TTKFESFLT3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290420-B1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | UNIV XIAMEN (CN) | 2020-12-09 | — | — | EP | claimed |
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2018-11-01 | — | — | US | claimed |
| EP-3290420-A1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Xiamen University (CN) | 2018-03-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | TPMT, DHPS, TYMP | PTK2 4325/4885STAT6 640/4885TTK 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.